FDA Accepts Krystal Biotech’s Biologics License Application for Dystrophic Epidermolysis Bullosa
August 18, 2022 17:00 ET
|
Krystal Biotech, Inc.
FDA granted Priority Review designationPDUFA target action date is February 17, 2023FDA stated that it is not currently planning to hold an advisory committee meeting PITTSBURGH, Aug. 18, 2022 ...
Krystal Biotech Announces Second Quarter 2022 Financial Results and Reports Updates on Operational Progress
August 08, 2022 07:00 ET
|
Krystal Biotech, Inc.
Biologics License Application for B-VEC filed with the FDA on June 22, 2022FDA accepts IND on KB407 for the treatment of Cystic FibrosisStrong balance sheet, closing the quarter with $438.5 million in...
Krystal Biotech Announces FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial
August 01, 2022 18:39 ET
|
Krystal Biotech, Inc.
KB407 is an investigational, redosable gene therapy candidate designed to treat all patients with cystic fibrosis regardless of the underlying genetic mutation PITTSBURGH, Aug. 01, 2022 (GLOBE...
Krystal Biotech Receives FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial
August 01, 2022 07:00 ET
|
Krystal Biotech, Inc.
KB407 is an investigational, redosable gene therapy candidate designed to treat all patients with cystic fibrosis regardless of the underlying genetic mutation PITTSBURGH, Aug. 01, 2022 (GLOBE...
Krystal Biotech to Present at William Blair Biotech Focus Conference 2022
July 06, 2022 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, July 06, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the...
Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa
June 22, 2022 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, June 22, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today the submission of a Biologics License...
Krystal Biotech to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
June 07, 2022 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, June 07, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the...
Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting
May 19, 2022 19:30 ET
|
Krystal Biotech, Inc.
PITTSBURGH, May 19, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, is pleased to present new data entitled “GEM-3: phase 3...
Krystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on Operational Progress
May 09, 2022 16:15 ET
|
Krystal Biotech, Inc.
Biologics License Application for B-VEC remains on track to file in the US in 2Q 2022 and Marketing Authorization in the EU on track to file in 2H 2022FDA allows dosing at a patient’s home in the Open...
Krystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare Conference
May 03, 2022 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, May 03, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief...